- Home
- MNPR vs FACT Comparison
MNPR vs FACT Comparison
Compare MNPR & FACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- FACT
- Stock Information
- Founded
- MNPR 2014
- FACT 2024
- Country
- MNPR United States
- FACT United States
- Employees
- MNPR N/A
- FACT N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- FACT
- Sector
- MNPR Health Care
- FACT
- Exchange
- MNPR Nasdaq
- FACT NYSE
- Market Cap
- MNPR 244.1M
- FACT 250.5M
- IPO Year
- MNPR 2019
- FACT 2024
- Fundamental
- Price
- MNPR $40.33
- FACT $10.03
- Analyst Decision
- MNPR Strong Buy
- FACT
- Analyst Count
- MNPR 5
- FACT 0
- Target Price
- MNPR $49.60
- FACT N/A
- AVG Volume (30 Days)
- MNPR 30.6K
- FACT 47.4K
- Earning Date
- MNPR 05-08-2025
- FACT 01-01-0001
- Dividend Yield
- MNPR N/A
- FACT N/A
- EPS Growth
- MNPR N/A
- FACT N/A
- EPS
- MNPR N/A
- FACT N/A
- Revenue
- MNPR N/A
- FACT N/A
- Revenue This Year
- MNPR $34.06
- FACT N/A
- Revenue Next Year
- MNPR N/A
- FACT N/A
- P/E Ratio
- MNPR N/A
- FACT N/A
- Revenue Growth
- MNPR N/A
- FACT N/A
- 52 Week Low
- MNPR $1.72
- FACT $9.85
- 52 Week High
- MNPR $54.30
- FACT $10.05
- Technical
- Relative Strength Index (RSI)
- MNPR 56.65
- FACT N/A
- Support Level
- MNPR $36.80
- FACT N/A
- Resistance Level
- MNPR $43.00
- FACT N/A
- Average True Range (ATR)
- MNPR 5.32
- FACT 0.00
- MACD
- MNPR 0.94
- FACT 0.00
- Stochastic Oscillator
- MNPR 63.41
- FACT 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About FACT FACT II ACQUISITION CORP
FACT II Acquisition Corp is a blank check company.